Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 10:53 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

ClinicalTrials.gov · NCT06804603 · Registry updated: 2025-11-12

Condition / research focus: Obesity
Sponsor: Vanda Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2025-02-25. Completion: 2025-10-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tradipitant (drug)
Placebo (drug)

Where the study takes place — 3 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Vanda Investigational Site
Los Angeles, California, United States
Site recruitment: Not reported
Vanda Investigational Site
Rochester, Minnesota, United States
Site recruitment: Not reported
Vanda Investigational Site
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Prevention of Progression of Prediabetes, Obesity and CV Risk

ClinicalTrials.gov · NCT06446531 · Registry updated: 2025-11-12

Condition / research focus: Pre-Diabetes; Weight, Body; Cardiovascular Diseases
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2024-09-11. Completion: 2027-07 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug) — also listed as: Zebbo
Rybelsus Tablet (drug) — also listed as: Semaglutide
Jardiance 25Mg Tablet (drug) — also listed as: Empagliflozin
Metformin (drug) — also listed as: Metformin Hydrochloride
Actos (drug) — also listed as: Pioglitazone

Where the study takes place — 1 listed sites

University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

ClinicalTrials.gov · NCT05768945 · Registry updated: 2025-11-10

Condition / research focus: Diabetes
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2022-11-30. Completion: 2023-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
DPP-4 inhibitor (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Tailored Exercise Training Study Among Adults With HFpEF

ClinicalTrials.gov · NCT07223242 · Registry updated: 2025-10-31

Condition / research focus: HFpEF - Heart Failure With Preserved Ejection Fraction; Diabetic Cardiomyopathies
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2025-02-18. Completion: 2026-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Moderate-intensity continuous training (MCT) (behavioral)
Resistance training (behavioral)
Weight loss (drug)

Where the study takes place — 1 listed sites

University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

ClinicalTrials.gov · NCT07064486 · Registry updated: 2025-10-28

Condition / research focus: Type 2 Diabetes (T2DM)
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Countries with listed sites: Indonesia
Registry dates and results: Start: 2025-07-04. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BGM0504 (drug)
BGM0504 (drug)
Semaglutide (drug)

Where the study takes place — 4 listed sites

RS Universitas Indonesia
Depok, West Java, Indonesia
Site recruitment: Recruiting
RSUP Fatmawati
Jakarta, Indonesia
Site recruitment: Recruiting
RSUP Persahabatan
Jakarta, Indonesia
Site recruitment: Recruiting
RSUPN Dr. Cipto Mangunkusumo
Jakarta, Indonesia
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

ClinicalTrials.gov · NCT06642584 · Registry updated: 2025-10-20

Condition / research focus: Healthy Volunteers Type 2 Diabetes
Sponsor: Novo Nordisk A/S
Countries with listed sites: Canada
Registry dates and results: Start: 2024-10-15. Completion: 2025-08-13 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide B (drug)
Semaglutide J (drug)
Semaglutide L (drug)
Semaglutide M (drug)
Semaglutide N (drug)

Where the study takes place — 1 listed sites

Altasciences
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims

ClinicalTrials.gov · NCT06659744 · Registry updated: 2025-10-15

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2024-10-24. Completion: 2025-03-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

New use of semaglutide injection (drug)
New initiation of sitagliptin (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

ClinicalTrials.gov · NCT07096063 · Registry updated: 2025-10-15

Condition / research focus: Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2024-10-01. Completion: 2025-07-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Dulaglutide (drug)
Semaglutide (drug)
Sitagliptin (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05443568 · Registry updated: 2025-10-06

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Israel
Registry dates and results: Start: 2023-03-09. Completion: 2024-11-16 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)

Where the study takes place — 1 listed sites

Master Centre for Israel
Kfar Saba, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

ClinicalTrials.gov · NCT05755360 · Registry updated: 2025-10-02

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Italy
Registry dates and results: Start: 2023-02-21. Completion: 2024-10-21 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 25 listed sites

Ospedale Pesenti Fenaroli
Alzano Lombardo, Italy
Site recruitment: Not reported
INRCA
Ancona, Italy
Site recruitment: Not reported
A.O.U. Policlinico S.Orsola
Bologna, Italy
Site recruitment: Not reported
Ospedale centrale L. Bohler
Bolzano, Italy
Site recruitment: Not reported
ASL Caserta
Caserta, Italy
Site recruitment: Not reported
Azienda Ospedaliera Cannizzaro
Catania, Italy
Site recruitment: Not reported
Azienda Sanitaria Locale Cn1
Cuneo, Italy
Site recruitment: Not reported
Università degli Studi Foggia
Foggia, Italy
Site recruitment: Not reported
Ospedale Misericordia
Grosseto, Italy
Site recruitment: Not reported
ASL Lecce
Lecce, Italy
Site recruitment: Not reported
Ospedale Pagliari
Massafra, Italy
Site recruitment: Not reported
ASL Avellino
Montoro, Italy
Site recruitment: Not reported
ASL Napoli 3 sud
Palma Campania, Italy
Site recruitment: Not reported
A.O.U. Maggiore della Carità
Piemonte, Italy
Site recruitment: Not reported
Ospedale San Jacopo
Pistoia, Italy
Site recruitment: Not reported
P.O. Praia a Mare
Praia a Mare, Italy
Site recruitment: Not reported
Ospedale Generale provinciale
Province of Macerata, Italy
Site recruitment: Not reported
ASL Roma 2 - UOC Cure Primarie Distretto 4
Roma, Italy
Site recruitment: Not reported
Fondazione Univ. Policlinico A.Gemelli
Roma, Italy
Site recruitment: Not reported
ASL Al Di Alessandria - Ospedale Santo Spirito - Casale Monferrato - Cardiologia
Roma, Italy
Site recruitment: Not reported
A.O.U. Policlinico Giaccone
Sicilia, Italy
Site recruitment: Not reported
Casa di cure Triolo Zancla
Sicilia, Italy
Site recruitment: Not reported
Ospedale Treviglio
Treviglio, Italy
Site recruitment: Not reported
Ospedale S. Maria della Misericordia
Udine, Italy
Site recruitment: Not reported
ASST Sette Laghi
Varese, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

ClinicalTrials.gov · NCT04466345 · Registry updated: 2025-10-02

Condition / research focus: Major Depressive Disorder
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2021-10-06. Completion: 2024-12-27 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (biological)
Placebo (biological)

Where the study takes place — 1 listed sites

Toronto Western Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Oral Semaglutide in Patients With Alzheimer's Disease

ClinicalTrials.gov · NCT07200622 · Registry updated: 2025-10-01

Condition / research focus: Alzheimer Disease
Sponsor: Imperial College London
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-09-25. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (Rybelsus®) (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Semaglutide for Helping Opioid Recovery

ClinicalTrials.gov · NCT06639464 · Registry updated: 2025-09-26

Condition / research focus: Opioid Use Disorder
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2025-06-02. Completion: 2026-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic
Placebo (other)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05443334 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Spain
Registry dates and results: Start: 2022-07-28. Completion: 2024-07-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Spain
Barcelona, Spain
Site recruitment: Not reported
Master Centre for Spain
Madrid, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

ClinicalTrials.gov · NCT05533632 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Chile
Registry dates and results: Start: 2022-04-25. Completion: 2024-01-18 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 3 listed sites

Servicios Médicos Godoy Limitada
Santiago, Región Metropolitana, Chile
Site recruitment: Not reported
Hospital San Juan de Dios_Santiago, Región Metropolitana
Santiago, Región Metropolitana, Chile
Site recruitment: Not reported
Hospital Padre Hurtado
Santiago, Región Metropolitana, Chile
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05230589 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Saudi Arabia
Registry dates and results: Start: 2022-04-25. Completion: 2023-03-13 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Saudi
Riyadh, Saudi Arabia
Site recruitment: Not reported
Specialized Medical Cente
Riyadh, Saudi Arabia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

ClinicalTrials.gov · NCT05996874 · Registry updated: 2025-09-24

Condition / research focus: Healthy Participants
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2023-08-12. Completion: 2024-04-18 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 1 listed sites

Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT04601740 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Netherlands
Registry dates and results: Start: 2020-11-17. Completion: 2022-12-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Semaglutide (drug)

Where the study takes place — 1 listed sites

Master Centre Netherlands
Alphen aan den Rijn, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05230615 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Italy
Registry dates and results: Start: 2022-04-01. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Italy
Rome, Italy
Site recruitment: Not reported
IRCCS MultiMedica
Sesto San Giovanni, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT04537637 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-08-28. Completion: 2023-05-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Denmark
Copenhagen S, Denmark
Site recruitment: Not reported
Novo Nordisk investigational site
Søborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 10:53 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

ClinicalTrials.gov · NCT06804603 · Registry updated: 2025-11-12

Condition / research focus: Obesity
Sponsor: Vanda Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2025-02-25. Completion: 2025-10-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tradipitant (drug)
Placebo (drug)

Where the study takes place — 3 listed sites

Vanda Investigational Site
Los Angeles, California, United States
Site recruitment: Not reported
Vanda Investigational Site
Rochester, Minnesota, United States
Site recruitment: Not reported
Vanda Investigational Site
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Prevention of Progression of Prediabetes, Obesity and CV Risk

ClinicalTrials.gov · NCT06446531 · Registry updated: 2025-11-12

Condition / research focus: Pre-Diabetes; Weight, Body; Cardiovascular Diseases
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2024-09-11. Completion: 2027-07 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug) — also listed as: Zebbo
Rybelsus Tablet (drug) — also listed as: Semaglutide
Jardiance 25Mg Tablet (drug) — also listed as: Empagliflozin
Metformin (drug) — also listed as: Metformin Hydrochloride
Actos (drug) — also listed as: Pioglitazone

Where the study takes place — 1 listed sites

University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

ClinicalTrials.gov · NCT05768945 · Registry updated: 2025-11-10

Condition / research focus: Diabetes
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2022-11-30. Completion: 2023-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
DPP-4 inhibitor (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Tailored Exercise Training Study Among Adults With HFpEF

ClinicalTrials.gov · NCT07223242 · Registry updated: 2025-10-31

Condition / research focus: HFpEF - Heart Failure With Preserved Ejection Fraction; Diabetic Cardiomyopathies
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2025-02-18. Completion: 2026-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Moderate-intensity continuous training (MCT) (behavioral)
Resistance training (behavioral)
Weight loss (drug)

Where the study takes place — 1 listed sites

University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

ClinicalTrials.gov · NCT07064486 · Registry updated: 2025-10-28

Condition / research focus: Type 2 Diabetes (T2DM)
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Countries with listed sites: Indonesia
Registry dates and results: Start: 2025-07-04. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BGM0504 (drug)
BGM0504 (drug)
Semaglutide (drug)

Where the study takes place — 4 listed sites

RS Universitas Indonesia
Depok, West Java, Indonesia
Site recruitment: Recruiting
RSUP Fatmawati
Jakarta, Indonesia
Site recruitment: Recruiting
RSUP Persahabatan
Jakarta, Indonesia
Site recruitment: Recruiting
RSUPN Dr. Cipto Mangunkusumo
Jakarta, Indonesia
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

ClinicalTrials.gov · NCT06642584 · Registry updated: 2025-10-20

Condition / research focus: Healthy Volunteers Type 2 Diabetes
Sponsor: Novo Nordisk A/S
Countries with listed sites: Canada
Registry dates and results: Start: 2024-10-15. Completion: 2025-08-13 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide B (drug)
Semaglutide J (drug)
Semaglutide L (drug)
Semaglutide M (drug)
Semaglutide N (drug)

Where the study takes place — 1 listed sites

Altasciences
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims

ClinicalTrials.gov · NCT06659744 · Registry updated: 2025-10-15

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2024-10-24. Completion: 2025-03-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

New use of semaglutide injection (drug)
New initiation of sitagliptin (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

ClinicalTrials.gov · NCT07096063 · Registry updated: 2025-10-15

Condition / research focus: Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2024-10-01. Completion: 2025-07-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Dulaglutide (drug)
Semaglutide (drug)
Sitagliptin (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05443568 · Registry updated: 2025-10-06

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Israel
Registry dates and results: Start: 2023-03-09. Completion: 2024-11-16 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)

Where the study takes place — 1 listed sites

Master Centre for Israel
Kfar Saba, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

ClinicalTrials.gov · NCT05755360 · Registry updated: 2025-10-02

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Italy
Registry dates and results: Start: 2023-02-21. Completion: 2024-10-21 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 25 listed sites

Ospedale Pesenti Fenaroli
Alzano Lombardo, Italy
Site recruitment: Not reported
INRCA
Ancona, Italy
Site recruitment: Not reported
A.O.U. Policlinico S.Orsola
Bologna, Italy
Site recruitment: Not reported
Ospedale centrale L. Bohler
Bolzano, Italy
Site recruitment: Not reported
ASL Caserta
Caserta, Italy
Site recruitment: Not reported
Azienda Ospedaliera Cannizzaro
Catania, Italy
Site recruitment: Not reported
Azienda Sanitaria Locale Cn1
Cuneo, Italy
Site recruitment: Not reported
Università degli Studi Foggia
Foggia, Italy
Site recruitment: Not reported
Ospedale Misericordia
Grosseto, Italy
Site recruitment: Not reported
ASL Lecce
Lecce, Italy
Site recruitment: Not reported
Ospedale Pagliari
Massafra, Italy
Site recruitment: Not reported
ASL Avellino
Montoro, Italy
Site recruitment: Not reported
ASL Napoli 3 sud
Palma Campania, Italy
Site recruitment: Not reported
A.O.U. Maggiore della Carità
Piemonte, Italy
Site recruitment: Not reported
Ospedale San Jacopo
Pistoia, Italy
Site recruitment: Not reported
P.O. Praia a Mare
Praia a Mare, Italy
Site recruitment: Not reported
Ospedale Generale provinciale
Province of Macerata, Italy
Site recruitment: Not reported
ASL Roma 2 - UOC Cure Primarie Distretto 4
Roma, Italy
Site recruitment: Not reported
Fondazione Univ. Policlinico A.Gemelli
Roma, Italy
Site recruitment: Not reported
ASL Al Di Alessandria - Ospedale Santo Spirito - Casale Monferrato - Cardiologia
Roma, Italy
Site recruitment: Not reported
A.O.U. Policlinico Giaccone
Sicilia, Italy
Site recruitment: Not reported
Casa di cure Triolo Zancla
Sicilia, Italy
Site recruitment: Not reported
Ospedale Treviglio
Treviglio, Italy
Site recruitment: Not reported
Ospedale S. Maria della Misericordia
Udine, Italy
Site recruitment: Not reported
ASST Sette Laghi
Varese, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

ClinicalTrials.gov · NCT04466345 · Registry updated: 2025-10-02

Condition / research focus: Major Depressive Disorder
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2021-10-06. Completion: 2024-12-27 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (biological)
Placebo (biological)

Where the study takes place — 1 listed sites

Toronto Western Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Oral Semaglutide in Patients With Alzheimer's Disease

ClinicalTrials.gov · NCT07200622 · Registry updated: 2025-10-01

Condition / research focus: Alzheimer Disease
Sponsor: Imperial College London
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-09-25. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (Rybelsus®) (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Semaglutide for Helping Opioid Recovery

ClinicalTrials.gov · NCT06639464 · Registry updated: 2025-09-26

Condition / research focus: Opioid Use Disorder
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2025-06-02. Completion: 2026-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic
Placebo (other)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05443334 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Spain
Registry dates and results: Start: 2022-07-28. Completion: 2024-07-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Spain
Barcelona, Spain
Site recruitment: Not reported
Master Centre for Spain
Madrid, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

ClinicalTrials.gov · NCT05533632 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Chile
Registry dates and results: Start: 2022-04-25. Completion: 2024-01-18 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 3 listed sites

Servicios Médicos Godoy Limitada
Santiago, Región Metropolitana, Chile
Site recruitment: Not reported
Hospital San Juan de Dios_Santiago, Región Metropolitana
Santiago, Región Metropolitana, Chile
Site recruitment: Not reported
Hospital Padre Hurtado
Santiago, Región Metropolitana, Chile
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05230589 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Saudi Arabia
Registry dates and results: Start: 2022-04-25. Completion: 2023-03-13 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Saudi
Riyadh, Saudi Arabia
Site recruitment: Not reported
Specialized Medical Cente
Riyadh, Saudi Arabia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

ClinicalTrials.gov · NCT05996874 · Registry updated: 2025-09-24

Condition / research focus: Healthy Participants
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2023-08-12. Completion: 2024-04-18 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 1 listed sites

Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT04601740 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Netherlands
Registry dates and results: Start: 2020-11-17. Completion: 2022-12-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Semaglutide (drug)

Where the study takes place — 1 listed sites

Master Centre Netherlands
Alphen aan den Rijn, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT05230615 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Italy
Registry dates and results: Start: 2022-04-01. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Italy
Rome, Italy
Site recruitment: Not reported
IRCCS MultiMedica
Sesto San Giovanni, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice

ClinicalTrials.gov · NCT04537637 · Registry updated: 2025-09-24

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-08-28. Completion: 2023-05-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Semaglutide (drug)

Where the study takes place — 2 listed sites

Master Centre for Denmark
Copenhagen S, Denmark
Site recruitment: Not reported
Novo Nordisk investigational site
Søborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →